Coronary artery disease risk factors in patients with schizophrenia: Effects of short term antipsychotic treatment

Simple item page
dc.contributor.buuauthorSarandöl, Aslı
dc.contributor.buuauthorKirli, Selçuk
dc.contributor.buuauthorAkkaya, Cengiz
dc.contributor.buuauthorOcak, Nihal
dc.contributor.buuauthorErol, Esma
dc.contributor.buuauthorSarandöl, Emre
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Bölümü.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-2593-7196tr_TR
dc.contributor.researcheridABE-1716-2020tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid23989248600tr_TR
dc.contributor.scopusid22950749100tr_TR
dc.contributor.scopusid55943324800tr_TR
dc.date.accessioned2022-09-07T13:11:23Z
dc.date.available2022-09-07T13:11:23Z
dc.date.issued2007-11
dc.description.abstractThe aim of the present study was to investigate serum paraoxonase/ arylesterase activities and oxidation/ oxidizability of apolipoprotein B- containing lipoproteins and several coronary artery disease risk factors, including homocysteine, high sensitive C- reactive protein, tumour necrosis factor- alpha, leptin and adiponectin in patients with schizophrenia. Oxidation of lipoproteins plays an important role in atherogenesis, and the enzyme paraoxonase has been shown to prevent lipoprotein oxidation. Furthermore, low paraoxonase activity has been suggested to predict coronary artery disease. Forty patients who fully met the fourth Diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia and 35 healthy control subjects were included in the study. Serum paraoxonase/ arylesterase activities were determined spectrophotometrically. Malondialdehyde levels of apolipoprotein B- containing lipoproteins were determined before and after incubation with copper- sulphate, which yielded basal- and Delta- malondialdehyde values, respectively. Homocysteine and highly sensitive C- reactive protein levels were determined using a fluorescence- polarization immunoassay and immunonephelometry, respectively. Leptin and adiponectin levels were measured with radioimmunoassay and tumour necrosis factor-alpha was determined by enzyme linked immunosorbent assay. Serum paraoxonase and arylesterase activities were significantly lower and Delta- malondialdehyde levels were significantly higher in the schizophrenia group compared with the control group. However, there were not any significant differences in other parameters of the study between the study groups. There was a significant increase in body mass index and serum triglyceride and very low density lipoprotein cholesterol levels in the schizophrenic group after 6 weeks of treatment. These parameters were significantly increased in patients treated with atypical antipsychotics but not in patients treated with typic or long acting antipsychotics. The results of the present study suggest that patients with schizophrenia might have increased risk for coronary artery disease related to reduced serum paraoxonase activity and increased oxidizability of apolipoprotein B- containing lipoproteins.en_US
dc.identifier.citationSarandöl, A. vd. (2007). "Coronary artery disease risk factors in patients with schizophrenia: Effects of short term antipsychotic treatment". Journal of Psychopharmacology, 21(8), 857-863.en_US
dc.identifier.endpage863tr_TR
dc.identifier.issn1461-7285
dc.identifier.issn0269-8811
dc.identifier.issue8tr_TR
dc.identifier.pubmed17715203tr_TR
dc.identifier.scopus2-s2.0-35649003173tr_TR
dc.identifier.startpage857tr_TR
dc.identifier.urihttps://doi.org/10.1177/0269881107077609
dc.identifier.urihttps://journals.sagepub.com/doi/10.1177/0269881107077609
dc.identifier.urihttp://hdl.handle.net/11452/28547
dc.identifier.volume21tr_TR
dc.identifier.wos000251688800012tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSage Publicationsen_US
dc.relation.journalJournal of Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdiponectinen_US
dc.subjectLow-density-lipoproteinen_US
dc.subjectAntipsychoticen_US
dc.subjectHigh sensitive C-reactive proteinen_US
dc.subjectHomocysteineen_US
dc.subjectLeptinen_US
dc.subjectLipoprotein oxidationen_US
dc.subjectParaoxonaseen_US
dc.subjectSchizophreniaen_US
dc.subjectTumour necrosis factor-αen_US
dc.subjectSerum paraoxonase arylesteraseen_US
dc.subjectIschemic-heart-diseaseen_US
dc.subjectNecrosis-factor-alphaen_US
dc.subjectCardiovascular-diseaseen_US
dc.subjectMethylenetetrahydrofolate reductaseen_US
dc.subjectAtypical antipsychoticsen_US
dc.subjectInsulin-resistanceen_US
dc.subjectAdiponectin levelsen_US
dc.subjectPromising markeren_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAnalytic methoden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAtherogenesisen_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeCardiovascular risken_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeTumor necrosis factor alphaen_US
dc.subject.emtreeCoronary artery diseaseen_US
dc.subject.emtreeDiagnostic and statistical manual of mental disordersen_US
dc.subject.emtreeEnzyme activityen_US
dc.subject.emtreeEnzyme linked immunosorbent assayen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeFluorescence polarization immunoassayen_US
dc.subject.emtreeLipid peroxidationen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeTriacylglycerol blood levelen_US
dc.subject.emtreeNephelometryen_US
dc.subject.emtreeOxidationen_US
dc.subject.emtreeRadioimmunoassayen_US
dc.subject.emtreeNeuroleptic agenten_US
dc.subject.emtreeSchizophreniaen_US
dc.subject.emtreeSpectrophotometryen_US
dc.subject.emtreeLipoproteinen_US
dc.subject.emtreeLow density lipoprotein cholesterolen_US
dc.subject.emtreeClozapineen_US
dc.subject.emtreeAdiponectinen_US
dc.subject.emtreeAmisulprideen_US
dc.subject.emtreeApolipoprotein Ben_US
dc.subject.emtreeAryldialkylphosphataseen_US
dc.subject.emtreeArylesteraseen_US
dc.subject.emtreeAtypical antipsychotic agenten_US
dc.subject.emtreeC reactive proteinen_US
dc.subject.emtreeHomocysteineen_US
dc.subject.emtreeCopper sulfateen_US
dc.subject.emtreeHaloperidolen_US
dc.subject.emtreeLeptinen_US
dc.subject.emtreeMalonaldehydeen_US
dc.subject.emtreeOlanzapineen_US
dc.subject.emtreeQuetiapineen_US
dc.subject.emtreeRisperidoneen_US
dc.subject.emtreeTriacylglycerolen_US
dc.subject.meshAdulten_US
dc.subject.meshAntipsychotic agentsen_US
dc.subject.meshAryldialkylphosphataseen_US
dc.subject.meshC-Reactive proteinen_US
dc.subject.meshFemaleen_US
dc.subject.meshCarboxylic ester hydrolasesen_US
dc.subject.meshCoronary artery diseaseen_US
dc.subject.meshHumansen_US
dc.subject.meshLeptinen_US
dc.subject.meshOxidation-reductionen_US
dc.subject.meshLipoproteinsen_US
dc.subject.meshMaleen_US
dc.subject.meshMalondialdehydeen_US
dc.subject.meshRisk factorsen_US
dc.subject.meshSchizophreniaen_US
dc.subject.meshTriglyceridesen_US
dc.subject.meshTumor necrosis factor-alphaen_US
dc.subject.scopusAryldialkylphosphatase; Arylesterase; Human PON1 Proteinen_US
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.titleCoronary artery disease risk factors in patients with schizophrenia: Effects of short term antipsychotic treatmenten_US
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus